Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.
This activity is intended for oncologists, pulmonologists, and pathologists.
The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 9, 2018- Nov. 9, 2019
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50